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Abstract
Exposure to lower-than-therapeutic levels of anti-tuberculosis drugs is likely to cause selec-
tion of resistant strains ofMycobacterium tuberculosis and treatment failure. The first-line
anti-tuberculosis (TB) regimen consists of rifampicin, isoniazid, pyrazinamide, and etham-
butol, and correct management reduces risk of TB relapse and development of drug resis-
tance. In this study we aimed to investigate the effect of standard of care plus nutritional
supplementation versus standard care on the pharmacokinetics of isoniazid, pyrazinamide
and ethambutol among sputum smear positive TB patients with and without HIV. In a clinical
trial in 100 Tanzanian TB patients, with or without HIV infection, drug concentrations were
determined at 1 week and 2 months post initiation of anti-TB medication. Data was analysed
using population pharmacokinetic modelling. The effect of body size was described using
allometric scaling, and the effects of nutritional supplementation, HIV, age, sex, CD4+
count, weight-adjusted dose, NAT2 genotype, and time on TB treatment were investigated.
The kinetics of all drugs was well characterised using first-order elimination and transit com-
partment absorption, with isoniazid and ethambutol described by two-compartment disposi-
tion models, and pyrazinamide by a one-compartment model. Patients with a slow NAT2
genotype had higher isoniazid exposure and a lower estimate of oral clearance (15.5 L/h)
than rapid/intermediate NAT2 genotype (26.1 L/h). Pyrazinamide clearance had an esti-
mated typical value of 3.32 L/h, and it was found to increase with time on treatment, with a
16.3% increase after the first 2 months of anti-TB treatment. The typical clearance of etham-
butol was estimated to be 40.7 L/h, and was found to decrease with age, at a rate of 1.41%
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Introduction
The aim of anti-tuberculosis (TB) treatment is to provide a safe, effective, and fast acting ther-
apy [1]. Isoniazid, pyrazinamide, and ethambutol constitute important companion drugs used
in a standard first-line short-course regimen together with rifampicin [2] and are believed to
eradicate aerobic, anaerobic, microaerophilic, and drug tolerant persisting bacteria [3]. While
isoniazid and pyrazinamide have bactericidal activity againstM. tuberculosis, ethambutol is
considered a bacteriostatic drug, though it may have bactericidal activity when given in higher
doses [2]. Treatment success rates of 88% were reported in Tanzania in 2011 using this regi-
men, thereby meeting the 85% target set by the World Health Assembly in 1993 [4, 5]. How-
ever, multidrug-resistance (MDR-TB) is emerging (1.1% of newly diagnosed TB cases in
Tanzania are MDR-TB) and may over time threat the standard first-line regimen [4, 5]. Previ-
ous studies have shown that low plasma anti-TB drug concentrations may result in treatment
failure [6, 7] and low plasma concentrations of rifampicin and isoniazid have been associated
with MDR-TB [8, 9]. Wide variability is reported in the pharmacokinetics (PK) of isoniazid,
pyrazinamide, and ethambutol [10–12], with factors such as age and HIV status and antiretro-
viral treatment (ART) possibly affecting TB drug concentrations [12–17]. Furthermore, malnu-
trition also seems to affect drug exposure by decreasing total clearance and increasing plasma
half-life [18]. Nutritional rehabilitation of children with kwashiorkor has been reported to
enhance isoniazid clearance [19], but the influence of administering nutritional supplementa-
tion to adult TB patients is unclear. We therefore conducted a randomized clinical trial in
Mwanza, Tanzania to examine the effect of nutritional supplementation on the pharmacoki-
netics of first-line anti-TB drugs in a cohort of pulmonary TB patients with or without HIV.
We recently reported the positive effect on a nutritional supplementation on rifampicin expo-
sure in the HIV co-infected patients (all ART naïve) [20]. In this analysis we aimed to investi-
gate the effect of standard of care plus nutritional supplementation vs. standard care on PK of
isoniazid, pyrazinamide, and ethambutol among sputum smear positive TB patients with and
without HIV. We also explored the effect of other covariates, including NAT2 genotype on the
PK of isoniazid.
Materials and Methods
Ethics Statement
Ethical permission to conduct the study was granted by the Medical Research Coordinating
Committee (MRCC) of the National Institute for Medical Research (NIMR) in Tanzania. Oral
and written information were provided in Swahili to all participants prior to obtaining
informed oral and written consent. Written consent was obtained from parents/legal guardians
of participants aged 15–17 years.
Study design, setting, and participants
The study was an open-label randomized clinical trial (ControlledTrials.com: ISRCTN
16552219) among 100 sputum smear positive TB patients, and details about the protocol are
available as supplementary information) (S1 Protocol). The study was conducted in the city of
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Mwanza, Tanzania between September 2010 and August 2011. Mwanza is the second largest
city in the country and is the region with the second highest number of TB case notification
(9.3%) after Dar es Salaam (21.9%) [5]. The study recruited newly diagnosed sputum positive
pulmonary TB patients aged 15 years or above. HIV-infected patients on ART, pregnant
women, critically ill patients not likely to survive> 48 hours, and non-residents of Mwanza
City were excluded.
TBmedication and intervention
The TB patients were administered TB medication according to the National Tuberculosis and
Leprosy Programme (NTLP) treatment guidelines [5], and those found co-infected with HIV
were managed according to National guidelines for the management of HIV and AIDS policy
[21]. The anti–TB drugs prescribed were formulated in fixed–dose combination (FDC) tablets
containing isoniazid (75 mg), rifampicin (150 mg), pyrazinamide (400 mg), and ethambutol
(275 mg) (Sandoz Pvt Ltd, India). Dosing was adjusted based on body weight: 3 tablets for
patients weighing up to 50 kg, and 4 tablets for those weighing more than 50 kg. The patients
were randomized to either receive or not receive nutritional supplementation in the form of
biscuits (Compact A/S, Bergen, Norway) containing high-energy (1000 kcal) and vitamin/min-
erals according to trial protocol [20]. A complete list of nutrients content is shown in Table 1.
Data collection
A standardised questionnaire was used to solicit demographic characteristics, previous TB his-
tory, and use of alcohol. Anthropometric measurements including weight and height were
obtained at each visit. All participants had a chest x-ray taken at recruitment and two indepen-
dent radiographers confirmed abnormalities.
Laboratory analyses
At recruitment, venous blood samples were collected. CD4+ lymphocyte count was analysed
using a Coulter1 Epics XL-MCL™ Flow Cytometer (Beckman Coulter, Brea, CA).
Table 1. Nutrients composition of the intervention used in the trial.
1 daily biscuit with the following micro nutrientsa
Vitamin A(5000IU)
Vitamin B1 (20mg)
Vitamin B2 (20mg)
Vitamin B6 (25mg)
Vitamin B12 (50mg)
Folic acid (0.8mg)
Niacin (40mg)
Vitamin C (200mg)
Vitamin E (60mg)
Vitamin D3 (200iu)
Selenium 0.2 mg
Copper (5mg)
Zinc (30mg)
Plus 4 additional daily biscuit with energy-protein
aDuration of intervention 60 days
doi:10.1371/journal.pone.0141002.t001
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Haemoglobin level and white blood cell counts were analysed using haematological Coulter
AcT 5 diff, (Beckman Coulter, Brea, CA). HIV status was determined on two rapid tests done
in parallel (SD Bioline HIV-1/2 3.0, Standard Diagnostics Inc., Kyonggi-do, South Korea;
Determine HIV-1/HIV-2, Inverness Medical Innovations Inc., Delaware, USA). Discordant
HIV test results were resolved using HIV UNIFORM II ELISA (Organon Teknia Ltd, Boxtel,
Netherlands),
Pharmacokinetic plasma sample collection, processing and analysis
Patients were scheduled for plasma sample collection on two occasions: at one week and two
months post-initiation of anti-TB medication. One day before blood sampling patients were
instructed to fast overnight, and on the morning of the PK visit, the study nurse administered the
anti-TB drugs according to body weight. Whole blood was collected in 5 mL of lithium heparin
tubes at 2, 4, and 6 hours post-dose. Samples were immediately centrifuged at 3000 rpm for
10 min to separate the plasma and transferred to -80°C within 30 minutes. The plasma samples
were then transported in dry ice to the Division of Clinical Pharmacology, University of Cape
Town, South Africa, for determination of isoniazid, pyrazinamide, and ethambutol concentra-
tions using validated tandemmass spectrometry high-performance liquid chromatography
(LC-MS/MS) methods. An AB Sciex API mass spectrometer was operated in the multiple reac-
tions monitoring (MRM) mode. The assays were validated over the concentration range of 0.112
to 26 mg/L for isoniazid, 0.203 to 81.1 mg/L for pyrazinamide and 0.081 to 5.18 mg/L for etham-
butol. The mean percentage accuracies during inter-day sample analysis at low, medium, and
high quality control levels, respectively, were 98.2%, 99.3%, and 94.7% for isoniazid, 97.8%,
102.1%, and 100.5% for pyrazinamide, and 99%, 101.3%, and 99.6% for ethambutol. The preci-
sion coefficient of variation for determination at low, medium, and high quality control level for
both pyrazinamide and ethambutol was less than 4% and for isoniazid less than 5%. Concentra-
tions below the validation range of the assay were reported as below the lower limit of quantifica-
tion (BLQ).
DNA extraction and NAT2 analysis
Serum aliquots for N-acetyltransferase-2 (NAT2) genotype were kept under -80°C until ana-
lyzed. Genotyping was carried out at the Statens Serum Institut, Copenhagen, DK after DNA
was extracted from blood using QIAamp DNA minikit (Qiagen GmbH, Hilden, Germany). An
annealing temperature of 60°C was used in all polymerase chain reactions (PCR). The PCR
products were sequenced using BigDye Terminator v1.1 Cycle Resequencing (ABI), and ana-
lyzed on an ABI3730 DNA Analyzer. The resulting sequences were compared to NCBI acces-
sion no. NG_012246.1 N-acetyltransferase-2 (NAT2) using Sequencer 5.0 software (Gene
Codes, Ann Arbor, USA). NAT2 haplotypes were based on dbSNP IDs: c.282C>T
(rs1041983), c.341T>C (rs1801280), c.481C>T (rs1799929), c.590G>A (rs1799930),
c.803A>G (rs1208) and c.857G>A (rs1799931) and the acetylator phenotype was inferred
using NAT2PRED (http://nat2pred.rit.albany.edu/).
Nonlinear mixed-effects modelling analysis
Nonlinear mixed-effects modelling was employed to interpret the data with the software NON-
MEM 7.3 [22], and the algorithm First-Order Conditional Estimation with eta-epsilon interac-
tion. Pirana, Perl-speaks-NONMEM, and xpose4 were used to aid the modelling process and
prepare model diagnostics [23]. The modelling procedure was similar for all drugs, as outlined
below. Several structural models were tested: one- and two-compartment disposition kinetics
with first-order elimination and several approaches for absorption: first-order, lagged first-
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order and transit compartment absorption [24]. The statistical model assumed log-normal dis-
tribution for the between-subject and–occasion random effects, and a combined additive and
proportional structure for the residual unexplained variability, with the additive component of
the error bound to be at least 20% of the lower limit of quantification (LLOQ). Allometric scal-
ing with either total body weight (WT) or fat-free mass (FFM) was applied to all clearances
(CL and Q) and volumes of distribution (Vc and Vp), as advocated by Anderson and Holford
[25]. The effect of other covariates was tested and included in the model based on significant
decreases (p<0.05) in the Objective Function Value (OFV) and physiological plausibility.
Covariates tested for effects on PK parameters were: HIV co-infection, nutritional supplemen-
tation, age, sex, CD4+ lymphocyte count, daily weight-adjusted dose, and time on TB treat-
ment. Additionally, NAT2 acetylator status was tested on isoniazid PK. The OFV, goodness of
fit plots, and Visual Predictive Checks (VPC) guided model development. The robustness of
the final parameter estimates was assessed with a non-parametric bootstrap. The post-hoc indi-
vidual parameter estimates from the final model were used to obtain the exposure parameters
Cmax and AUC0-24. These individual values were calculated to provide summary values for
comparison with previous studies, but they were not used. with the purpose of statistical infer-
ence, since they are dependent on the model and they are affected by statistical shrinkage (espe-
cially Cmax)[26].
Results
A total of 100 newly diagnosed pulmonary TB patients were enrolled in the study (Fig 1). The
sex and HIV status distributions were almost even, with 42% (n = 42) women and 50 HIV co-
infected. The median (IQR) age was 35 years (29; 40) and weight was 51.9 kg (48.2; 57.3). As
many as 48 subjects were classified as NAT2 slow acetylators, 48 as intermediate, and 2 as
rapid acetylators, while the acetylator status of 2 subjects could not be determined. Baseline
characteristics are shown in Table 2.
A total of 192 isoniazid PK profiles were obtained from 100 patients, based on 574 plasma
concentration measurements, three of which were BLQ. The final structural model was a two-
compartment disposition with transit compartment absorption. The data did not support sig-
nificantly different estimates for the absorption rate constant (ka) and for the rate constants
between the transit compartments (ktr), so the absorption model was simplified. Fat-free mass
(FFM) was found to be the most suitable size descriptor for allometric scaling. The model sup-
ported between-subject variability in clearance and between-occasion variability in bioavail-
ability and mean absorption transit time (MTT). The population pharmacokinetic final
parameter estimates are shown in Table 3, and a visual predictive check is shown in Fig 2.The
model detected a significant effect of NAT2 acetylator status on CL (51.4 points improvement
in OFV, p<10−6). Subjects with slow NAT2 genotype had a lower clearance (15.5 L/h) com-
pared to rapid or intermediate NAT2 (26.1 L/h). For the two subjects with undetermined
NAT2 acetylator status, their values were imputed using a mixture model taking into account
both their observed isoniazid concentrations and the relative frequency of each genotype in the
rest of the study population, as suggested in Keizer et al. [27]. The model did not detect signifi-
cant effects of HIV or nutritional supplementation on clearance or bioavailability. The individ-
ual values of Cmax and AUC0-24h, stratified by NAT2 genotype are shown in Fig 3. Among the
slow NAT2 acetylators, median AUC0-24 and Cmax were 17.1 hmg/L (IQR: 14.7; 21.2) and 3.53
mg/L (IQR: 3.09; 3.83), respectively. The subjects categorised as rapid or intermediate NAT2
acetylators achieved lower median AUC0-24 and Cmax: 9.89 hmg/L (IQR: 7.99; 12.1) and 3.03
mg/L (IQR: 2.76; 3.49), respectively.
Pharmacokinetics of INH PZA and EMB in TB Patients
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For pyrazinamide and ethambutol, only116 PK profiles from 98 patients based on 346
plasma concentrations, were included in the PK modelling. Since many patients had already
been switched to the continuation phase of treatment, comprised only of isoniazid and rifampi-
cin, at the time of the second PK visit, the number of analysed patients is lower than for the iso-
niazid studies (n = 18). No plasma concentrations were BLQ.
For pyrazinamide, the best model was a one-compartment disposition, first-order elimina-
tion, and transit compartment absorption with no separate estimate of absorption rate con-
stants (ktransit = ka). The final parameter estimates are included in Table 4, while a visual
predictive check is shown in Fig 4. The best size predictor for allometric scaling of clearance
was total body weight, while volume of distribution was better scaled with fat-free mass.
Fig 1. Flow chart for pulmonary TB-positive patients randomized to receive a nutritional supplement or no supplement and followed for the effects
of nutritional supplementation on Isoniazid, Pyrazinamide and Ethambutal exposure at the end of the secondmonth of intensive phase of
treatment.
doi:10.1371/journal.pone.0141002.g001
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Table 2. Baseline characteristics of 100 pulmonary sputum smear positive patients starting TB
treatment.
Characteristics Valuesa
Age (years) 35 (29; 40)
Sex (Males) 58 (58.0)
Weight (kg) 51.9 (48.3; 57.3)
Body mass index (kg/m2) 18.8 (17.3; 19.9)
Haemoglobin (g/dL)b 111 (93; 125)
White blood cell (x 109/L)b 6.6 (4.6; 9.1)
CD4+ count (cell/μL)b 375 (160; 642)
HIV infected 50 (50.0)
TB cavitations present 28 (32.2)
Fasting blood glucose (mmol/L) 6 (5.4; 6.6)
Nutritional supplementation
No Supplementation 49 (49.0)
Received supplementation 51 (51.0)
NAT2 phenotype
Slow 48(48.0)
Intermediate 48 (48.0)
Rapid 2 (2.0)
Unknown 2 (2.0)
aData are median (IQR) or n (%).
bThe total number of observations was not 100 due to missing values.
doi:10.1371/journal.pone.0141002.t002
Table 3. Isoniazid pharmacokinetics parameter estimates among newly diagnosed sputum smear
positive TB patients.
Parameter description Typical value
Estimate (90% CI)c
Clearance for rapid/intermediate NAT2 acetylatorsa(L/h) 26.1 (23.6; 29.5)
Clearance for slow NAT2 acetylatorsa (L/h) 15.5 (14.3; 16.7)
Central volume of distributiona - Vc (L) 48.2 (18.7; 56.4)
Inter-compartmental clearancea Q (L/h) 16.1 (7.5; 61.6)
Peripheral volumea Vp(L) 16.5 (12.4; 45.4)
Mean transit time “MTT” (h) 0.924 (0.78; 1.33)
Number of transit compartment–“NN” 2.73 (1.15; 5.49)
Bioavailability–“F” 1 FIXED
Proportional error (%) 13.3 (11.7; 14.4)
Additive error (mg/L) 0.0224 FIXED
Between subject variability of clearanceb (%CV) 30.7 [6%] (24.8; 35.5)
Between occasion variability of mean transit timeb (%CV) 37.4 [29%] (25.8; 41.7)
Between occasion variability of bioavailabilityb (%CV) 12.8 [79%] (11.1; 15.7)
aAllometric scaling was used for CL, Vc, Q, and Vp,so the typical values are reported for the median fat-
free mass of the cohort (43 kg)
bThe between-subject and–occasion variability was assumed log-normally distributed and is reported here
as approximate %CV. In square brackets, the value of shrinkage.
cThe precision of the estimates was obtained with a non-parametric 90% conﬁdence interval based on a
500 sample bootstrap
doi:10.1371/journal.pone.0141002.t003
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Pyrazinamide clearance increased with time on treatment: the model estimated 16.3% faster
clearance from the data collected after more than 18 days of treatment (-6.96 OFV, p<0.01).
This break point was chosen to include all PK profiles from the second PK visit, mostly col-
lected 2 months after treatment initiation, plus two late-comers for the first PK occasion (on
days 19 and 26). Other factors including HIV status, nutritional supplementation, age, sex,
CD4 count, and weight-adjusted dose were tested in the model, but did not significantly influ-
ence pyrazinamide PK. The relationship between these individual values of pyrazinamide
exposure and time on TB treatment is shown in Fig 5. Among the PK profiles obtained in the
first 2 weeks of TB treatment, median pyrazinamide AUC0-24 and Cmax were 413 hmg/L (IQR:
337; 546) and 37.8 mg/L (IQR: 32.8; 44.5), respectively. For the profiles collected after 2 weeks
of TB treatment AUC0-24 and Cmax decreased to 364 hmg/L (IQR: 277; 433) and 32.4 mg/L
(IQR: 30.9; 37.5), respectively.
For ethambutol, the best-fitting model was a two-compartment disposition, with first-order
elimination, and transit compartment absorption with no separate estimate of ka. The final
parameter estimates are shown in Table 5 and a visual predictive check is shown in Fig 6.
Although the inclusion of two-compartment disposition kinetics significantly improved the
model fit (-30 points OFV), the parameter estimates for the volume of the peripheral
Fig 2. Visual predictive check (VPC) for isoniazid concentration versus time, stratified by NAT2 acetylator status (extensive and intermediate on
the left, slow on the right). The circles represent the original data, the dashed and solid lines are the 5th, 50th, and 95th percentiles of the original data, while
the shaded areas are the corresponding 95% confidence intervals for the same percentiles, as predicted by the model.
doi:10.1371/journal.pone.0141002.g002
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compartment (Vp) and the inter-compartmental clearance (Q) proved unstable. To stabilise
the model while allowing the inclusion of the two-compartment kinetics, a prior was included
[28], based on parameter estimates from a PK model of ethambutol developed on data from a
similar population of TB patients [29]. After applying allometric scaling to adjust for differ-
ences in body weight amongst the studies, the typical values for the priors of Vp and Q were
420.7 L/h and 64.4 L/h, respectively. The priors were assumed to have a Gaussian distribution
around these typical values, and were included in the model imputing a large uncertainty (50%
CV) to make them weakly informative. Testing different settings for the prior distributions
showed that the estimates of the other parameters in the model were not significantly affected.
After the inclusion of the priors, the two-compartment model proved stable and provided a sig-
nificantly better fit than the one-compartment model, and was used for the analysis. The best
predictor for allometric scaling of all clearance and volume parameters was total body weight.
Additionally, older age was associated with lower clearance, with every year of age causing a
Fig 3. Box and whisker plots showing isoniazid exposure vs. time NAT2 acetylator status (grouped as rapid or intermediate together vs. slow). The
left panel displays AUC0-24 and the right panel Cmax. The dots represent individual values. Since for most subjects 2 PK profiles were available, geometric
mean was used to summarize the individual values.
doi:10.1371/journal.pone.0141002.g003
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decrease of 1.41% in clearance (-23.4 OFV, p<10 -5). No other factors tested in the model,
including HIV status, nutritional supplementation, sex, CD4 count, and time on TB treatment,
significantly affected the PK. The relationship between the individual values of ethambutol
exposure and age is shown in Fig 7. Median ethambutol AUC0-24 was 23.6 hmg/L (IQR: 20.5;
28.9) and Cmax was 2.44 mg/L (IQR: 2.09; 2.86).
Discussion
We studied the effect of nutritional supplementation and HIV status on the pharmacokinetics
of isoniazid, pyrazinamide, and ethambutol in pulmonary TB patients during the intensive
phase of a standard course of TB treatment.
Malnutrition is a well-known companion to both HIV and TB, and food programs are
therefore being launched in many Sub-Saharan regions to alleviate this problem. Nutritional
supplementation has previously been reported to improve treatment outcome in both TB and
HIV patients [30, 31], so our study aimed to investigate if nutritional intervention is affecting
the PK exposure of the first-line TB drugs. We recently published the beneficial effect of nutri-
tional supplementation on rifampicin exposure, especially in HIV positive TB patients [20]. In
the current study, we found that nutritional supplementation had no effect on isoniazid, pyra-
zinamide, and ethambutol exposure, and there was no effect of HIV co-infection. The effect of
nutritional supplements may depend on the individual’s baseline micronutrients status and
only cause an effect in undernourished subjects [32]. In our cohort, baseline BMI was 18.8
Table 4. Pyrazinamide pharmacokinetics parameter estimates among newly diagnosed sputum
smear positive pulmonary TB patients.
Parameter description Typical value
Estimate (90% CI)d
Clearancea–CL (L/h) 3.32 (3.10; 3.53)
Volume of distributiona –Vd (L) 40.1 (38.4; 42.1)
Absorption mean transit time—“MTT” (h) 0.84 (0.42; 1.08)
Number of absorption transit compartments–NN 2.6 (0.2; 7.3)
Bioavailability–F 1 FIXED
Clearance change after 2 months of treatmentb (+%) 16.3 (2.6; 29.2)
Proportional error (%) 7.2 (6.0; 8.1)
Additive error (mg/L) 0.041 FIXED
Between-subject variability in clearancec (%CV) 22.6 [28%] (11.7; 30.8)
Between-occasion variability in clearancec (%CV) 19.3 [40%] (2.0; 28.2)
Between-occasion variability in mean transit timec (%CV) 46.9 [38%] (32.3; 89.9)
Between-occasion variability in bioavailabilityc (%CV) 10.1 [39%] (4.6; 13.2)
aAllometric scaling was used for clearance (total weight) and volume of distribution (fat-free mass), so the
values are reported for the median weight (52 kg) and fat-free mass (43 kg) of the cohort.
bAlthough nearly all the proﬁles with increased clearance were collected at ~2 months after TB treatment
initiation, the cut-off used in the model was 18 days.
cThe between-subject and–occasion variability was assumed log-normally distributed and is reported here
as approximate %CV. In square brackets, the value of shrinkage.
dThe precision of the estimates was obtained with a non-parametric 90% conﬁdence interval based on a
500-sample bootstrap.
doi:10.1371/journal.pone.0141002.t004
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(IQR 17.3; 19.9) which classifies most of the participants in the category of underweight; how-
ever, we did not assess their micronutrient status.
We further assessed predictors that potentially could influence the PK, including the NAT2
genotype, age of the patient, and timing of the sampling with respect to treatment initiation.
The NAT2 gene product is expressed in the liver and small intestine, constituting an important
phase II enzyme responsible for acetylating isoniazid [33]. NAT2 activities may vary due to dif-
ferences in the NAT2 alleles or haplotypes caused by Single-Nucleotide Polymorphisms
(SNPs) [33]. As expected, NAT2 genotype strongly influenced isoniazid pharmacokinetics.
Patients categorized as slow NAT2 acetylators had a lower clearance (typical value 15.5 vs. 26.1
L/h) and higher estimated isoniazid exposures (AUC0-24 of 17.1 vs. 9.89 hmg/L).compared to
rapid or intermediate NAT2 acetylators. The distribution of NAT2 genotypes is comparable to
what was found by Sabbagh et al. and Matimba et al. who reported a high prevalence of slow
and intermediate acetylators in African populations, due to the common NAT25, 6, and 14
polymorphisms [34, 35]. Our findings are in line with those reported by Conte et al. examining
the effects of gender, AIDS, and acetylator status on the steady-state concentrations of orally
administered isoniazid in plasma and lungs [36]. Similar findings were reported by Chen et al.
assessing the influence of NAT2 genotype on the plasma concentration of isoniazid and acetyl-
Fig 4. Visual predictive check (VPC) for pyrazinamide concentration versus time, stratified by time on TB treatment. The circles represent the
original data, the dashed and solid lines are the 5th, 50th, and 95th percentiles of the original data, while the shaded areas are the corresponding 95%
confidence intervals for the same percentiles, as predicted by the model.
doi:10.1371/journal.pone.0141002.g004
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isoniazid in a Chinese population [37]. Pasipanodya et al. have compiled these results in a
meta-analysis and suggest that this genetic variability is a contributing factor for microbiolog-
ical treatment failure [9].
When characterising pyrazinamide PK, we found that clearance increases with time on
treatment, an observation also recently reported by Chirehwa et al, in South African TB
patients co-infected with HIV [38]. They detected an increase of 19% in clearance by day 28
after treatment initiation, which is comparable with our finding of a 16.3% increase. During TB
treatment, pyrazinamide is given concomitantly (or even co-formulated) with rifampicin,
which is a well-known potent inducer of hepatic and intestinal CYP3A subfamily and many
other metabolic pathways via activation of the pregnane X-receptor (PXR) [39]. For this rea-
son, rifampicin exposure results in increasing clearance of many co-administered drugs, and it
could be speculated that rifampicin may induce microsomal deamidase or some other pathway,
thus enhancing pyrazinamide clearance [38]. On the other hand, the observed increase in clear-
ance could also be the effect of the overall improvement in health conditions of the patients
Fig 5. Box and whisker plots showing pyrazinamide exposure vs. time on TB treatment (approximately less or more than 2 weeks). The left panel
displays AUC0-24 and the right panel Cmax. The dots represent individual values. When 2 PK profiles were available in the same stratum, geometric mean
was used to summarize the value.
doi:10.1371/journal.pone.0141002.g005
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after treatment initiation. The pyrazinamide exposures we observed did not significantly devi-
ate from previous results [40–44]. In the current study, the estimates for median pyrazinamide
Cmax and AUC0-24 were in line with previous reports showing median Cmax levels ranging from
27 to 38 mg/L and AUC0-24 between 321 and 418 hmg/L [41–44]. Our results also confirm the
reports by Fahimi et al. and Tappero et al. who showed that the majority of patients achieve
pyrazinamide plasma exposures within a range relatively narrower than other TB drugs, due to
its efficient absorption [45, 46]. Pasipanodya et al. recently investigated the TB drug concentra-
tion levels that are predictive of TB treatment outcome, and they reported that pyrazinamide
peak concentration 58.3 mg/L was associated with poor 2-month sputum conversion, while
AUC0-24 363 hmg/L was one of the predictors of poor long term outcome [7]. In their analy-
sis, PK exposures were measured at 2 months after treatment initiation. In our cohort, only
one PK profile had Cmax above the proposed threshold at around 2 months after treatment ini-
tiation. The overall median Cmax was 32.4 mg/L, while the median pyrazinamide AUC0-24 at
around 2 months after treatment initiation was 364 hmg/L, and a similar value is obtained
when adjusting the median AUC0-24 observed after 1 week to account for the estimated
increase in clearance, i.e., multiplying by 1/(1+16.3%). More specifically, we found that 31.6%
of this population had pyrazinamide AUC0-24 363 hmg/L around 1 week and 55.6% at
around 2 months after TB treatment initiation. This means that about half of the patients in
our cohort achieved exposures below the proposed AUC threshold, and nearly none achieved
Table 5. Ethambutol pharmacokinetics parameter estimates among newly diagnosed sputum smear
positive pulmonary TB patients.
Parameter description Typical value
Estimate (90% CI)e
Clearancea,b –CL (L/h) 40.7 (35.7; 45.2)
Central volume of distributiona - Vc (L) 266 (207; 326)
Inter-compartmental clearancea,c - Q (L/h) 109 (82; 136)
Peripheral volume of distributiona,c - Vp (L) 687 (493; 850)
Absorption mean transit time—“MTT” (h) 2.54 (2.32; 2.78)
Number of absorption transit compartments–NN 11.1 (6.0; 30.2)
Bioavailability–F 1 FIXED
Effect of age on Clearance (% change per year) -1.41 (-1.76; -1.09)
Proportional error (%) 22.5 (19.1; 24.5)
Additive error (mg/L) 0.0162 FIXED
Between-subject variability in bioavailabilityd (%CV) 21.5 [14%] (15.7; 26.2)
Between-occasion variability in mean transit timed (%CV) 26.1 [14%] (16.9; 33.7)
aAllometric scaling was used for CL, Vc, Q, and Vp, so the values are reported for the median weight of the
cohort (52 kg).
bCL was affected by age, the typical value reported here refers to the median age in the cohort (35 years)
cQ and Vp were estimated using Gaussian priors with typical values 64.4 L/h and 420.7 L respectively, and
50% uncertainty.
dThe between-subject and–occasion variability was assumed log-normally distributed and is reported here
as approximate %CV. In square brackets, the value of shrinkage.
eThe precision of the estimates was obtained with a non-parametric 90% conﬁdence interval based on a
500 sample bootstrap
doi:10.1371/journal.pone.0141002.t005
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Cmax above the cut-off. Unfortunately, our study was not powered to assess the long-term effect
of drug exposure on treatment outcome.
Ethambutol plasma concentrations among our study participants were relatively low com-
pared with previous studies [10, 40–42, 44], reporting median Cmax ranging from 2.7 to 4.8
mg/L and median AUC0-24 between 20 and 47 hmg/L. In our cohort, median ethambutol Cmax
was 2.44 mg/L and AUC0-24 was 23.6 hmg/L, values similar to those reported by Tappero et al.
and Um et al. [46, 47]. Ethambutol pharmacokinetics has been previously associated with
many factors including malnutrition, HIV infection, age, and sex [12, 42, 48–50]. In our cohort,
age was found to affect ethambutol clearance, with increasing age leading to lower clearance at
a decrease rate of 1.41% per year. A relationship between age and anti-TB drug plasma levels
has been previously reported in a study in South African patients [12], where it was suggested
that older patients have higher levels of ethambutol and isoniazid because of the functional
decrease of metabolic pathways and reduced renal clearance capacity. HIV infection was not
found to affect ethambutol plasma concentration in this population, in contrast to studies by
Zhu et al. [51] and Jonsson et al. [10], who both reported that HIV infection was associated
with a reduction in ethambutol concentrations.
Fig 6. Visual predictive check (VPC) for ethambutol concentration versus time. The circles represent
the original data, the dashed and solid lines are the 5th, 50th, and 95th percentiles of the original data, while
the shaded areas are the corresponding 95% confidence intervals for the same percentiles, as predicted by
the model.
doi:10.1371/journal.pone.0141002.g006
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Limitations and strengths
The number of PK samples collected at each visit was small, limiting the characterization of the
pharmacokinetic curve, as well as the precision of the individual estimates of exposure, espe-
cially Cmax. This was a compromise accepted in the study design to limit the time patients had
to spend at the clinic during PK sampling, as the patients involved were treated as outpatients.
The data was interpreted with nonlinear mixed-effects modelling, which appropriately handles
sparse sampling and supports the robustness of our findings.
Another limitation of the study is represented by the few PK profiles of pyrazinamide and
ethambutol available from the second visit (only 18 out of those that came back for the second
evaluation), since a majority of the patients had already been switched to the continuation
phase not including pyrazinamide and ethambutol. This missingness of the data reduced the
sample size for the investigation of the effect of the time on treatment, but nonlinear mixed-
Fig 7. In the left panels, scatter plots showing ethambutol exposure vs. patient age. In the right small panels, box and whiskers plots summarizing the
same values. The top panels refer to AUC0-24 and the bottom panels to Cmax. For all patients for whom 2 PK profiles were available, geometric mean was
used to obtain summary values.
doi:10.1371/journal.pone.0141002.g007
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effects modelling is known to handle these kinds of scenarios well. Moreover, the two cohorts
(patients in continuation vs intensive phase at PK visit 2) had similar demographic characteris-
tics and similar proportions of HIV infection and subjects randomised to supplementation
(data not shown).
This study was initiated and conducted before clear policies regarding the timing of ART to
HIV co-infected TB patients were established. Therefore pharmacologic interaction with vari-
ous ARTs is not an issue in this study.
Conclusions
In summary, we reported the pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in
a cohort of Tanzanian TB patients. We found that nutritional supplements with energy-protein
plus micronutrients given to TB patients during the intensive phase of a conventional TB regi-
men have no effect on the exposure of isoniazid, pyrazinamide, or ethambutol. HIV status did
not influence this result. Intermediate and rapid NAT2 genotypes were associated with lower
isoniazid exposure. Pyrazinamide clearance increased with time on treatment, which was asso-
ciated with lower serum pyrazinamide levels at the end of intensive phase of TB treatment. Eth-
ambutol plasma concentrations were relatively low in our cohort of Tanzanian patients
compared with previous studies, and older age was associated with lower clearance of
ethambutol.
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